SEC Form 4 · accession 0001209191-18-063175
ACHILLION PHARMACEUTICALS INC · ACHN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Scheer
Director
Period of report
Dec 14, 2018
Accepted (ET)
Dec 18, 2018 · 4:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001070336
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 14, 2018 | M | 20,000 | $1.05 | A | 20,000 | D | |
| Common StockF1 | holding | — | — | — | 63,249 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock OptionF2 | $1.05 | Dec 14, 2018 | M | 20,000 | D | — | Dec 15, 2018 | Common Stock | 20,000 | 0 | D |
Explanation of responses
- F1Consists of shares held by Scheer Investment Holdings III, LLC. Mr. Scheer is the Managing Member of Scheer Investment Holdings III, LLC. and as such may be deemed to have shared voting and investment power with respect to the shares held by Scheer Investment Holdings III, LLC. Mr. Scheer disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- F2This option was granted on December 15, 2008 and vested over a four year period with 25% of the shares vesting on the first anniversary of the grant date and an additional 6.25% vesting at the end of each three-month period thereafter.
Remarks
See Exhibit 24.1, Power of Attorney